News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
WUXI APPTEC: US Wrongly Includes Company on 'Chinese Military Companies' List; Company Will Take Measures to Challenge and Rectify
WUXI APPTEC (02359.HK) noted that the United States Department of Defense incorrectly included WuXi AppTec in its updated Section 1260H list of designated “Chinese military c...
Reset
Send
The window will close in 5 seconds
WUXI APPTEC: US Wrongly Includes Company on 'Chinese Military Companies' List; Company Will Take Measures to Challenge and Rectify
Close
Recommend
3
Positive
5
Negative
5
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

WUXI APPTEC (02359.HK)  +3.000 (+2.492%)    Short selling $230.93M; Ratio 24.410%   noted that the United States Department of Defense incorrectly included WuXi AppTec in its updated Section 1260H list of designated “Chinese military companies”. It believed that the designation of WuXi AppTec on this updated list, along with the alleged basis for the designation, was clearly a mistake, and WuXi AppTec will take immediate actions to challenge and correct this erroneous designation.

WuXi AppTec does not meet the statutory criteria for designation as a “Chinese military company.” The allegation basis for its 1260H list designation is factually incorrect given that: (i) it is not owned or controlled by or affiliated with any military or government entity of the People’s Republic of China (PRC); (ii) it does not provide services to the PRC military; and it is not associated with the PRC’s defense industrial base or military-civil fusion programs.

Related News WUXI APPTEC (02359.HK) Resilient Amid Market Weakness; UBS Says 1260H List Has Limited Fundamental Impact
WuXi AppTec is an independent, publicly traded company serving thousands of partners across over 30 countries to develop life-saving medicines for global patients. The integrity of its global operations is demonstrated by its track record, including more than 50 successful inspections by the United States, the European Union, and other regulators in 2025 alone, along with hundreds of customer audits.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-11 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.